Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
20 participants
OBSERVATIONAL
2025-12-15
2027-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants with or without Alzheimer's disease will have a brain imaging session where NAD will be measured using magnetic resonance spectroscopy (MRS). Eight months later, they will have a second, similar, brain imaging session.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Alzheimer's disease group
People diagnosed with Alzheimer's disease
No interventions assigned to this group
Control group
People without Alzheimer's disease
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 65 to 80 included.
* People with Alzheimer's disease (AD): AD diagnosis established by the person's physician according to the following criteria: clinical diagnosis AND either positive amyloid PET-scan or FDA-approved positive CSF or blood test.
Exclusion Criteria
* Advanced dementia such that the person would require sedation for undergoing an MRI scan.
* Receiving anti-amyloid intravenous treatments Leqembi or Kinsula.
* Having an MRI-incompatible pacemaker or other MRI-incompatible hardware (e.g. comprising a metallic part).
* Having a history of seizures.
* Working at night.
* Having cancer or having been diagnosed with cancer within the last 5 years (excluding superficial squameous or basal cell cancer).
* People with no AD: MoCA test result lower than 26.
65 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Florida Atlantic University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Corinne Lasmezas
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Corinne Lasmezas, PhD
Role: PRINCIPAL_INVESTIGATOR
Florida Atlantic University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
FAU Clinical Research Unit
Boca Raton, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB2504137
Identifier Type: -
Identifier Source: org_study_id